Pro Share Advisors LLC Bei Gene, Ltd. Transaction History

Pro Share Advisors LLC

  • $39.7 Billion
  • Q3 2024

A detailed history of Pro Share Advisors LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Pro Share Advisors LLC holds 2,615 shares of BGNE stock, worth $592,846. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,615
Previous 2,639 0.91%
Holding current value
$592,846
Previous $376,000 56.12%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$143.93 - $224.51 $3,454 - $5,388
-24 Reduced 0.91%
2,615 $587,000
Q2 2024

Aug 13, 2024
SELL
$129.52 - $174.32 $34,063 - $45,846
-263 Reduced 9.06%
2,639 $376,000
Q1 2024

May 08, 2024
BUY
$141.8 - $181.47 $30,770 - $39,378
217 Added 8.08%
2,902 $453,000
Q4 2023

Feb 14, 2024
SELL
$158.67 - $201.58 $10,313 - $13,102
-65 Reduced 2.36%
2,685 $484,000
Q3 2023

Nov 13, 2023
BUY
$179.87 - $225.13 $13,670 - $17,109
76 Added 2.84%
2,750 $494,000
Q2 2023

Aug 10, 2023
SELL
$178.3 - $266.78 $49,924 - $74,698
-280 Reduced 9.48%
2,674 $476,000
Q1 2023

May 11, 2023
SELL
$215.53 - $274.5 $215,961 - $275,049
-1,002 Reduced 25.33%
2,954 $636,000
Q4 2022

Feb 02, 2023
SELL
$125.51 - $229.3 $13,931 - $25,452
-111 Reduced 2.73%
3,956 $870,000
Q3 2022

Nov 04, 2022
BUY
$131.8 - $202.24 $31,236 - $47,930
237 Added 6.19%
4,067 $548,000
Q2 2022

Aug 01, 2022
SELL
$121.11 - $216.05 $160,107 - $285,618
-1,322 Reduced 25.66%
3,830 $620,000
Q1 2022

May 10, 2022
SELL
$146.52 - $269.56 $269,157 - $495,181
-1,837 Reduced 26.28%
5,152 $972,000
Q4 2021

Feb 08, 2022
SELL
$248.56 - $389.34 $965,655 - $1.51 Million
-3,885 Reduced 35.73%
6,989 $1.89 Million
Q3 2021

Nov 12, 2021
BUY
$249.6 - $403.14 $464,755 - $750,646
1,862 Added 20.66%
10,874 $3.95 Million
Q2 2021

Aug 13, 2021
BUY
$292.75 - $367.01 $640,537 - $803,017
2,188 Added 32.06%
9,012 $3.09 Million
Q1 2021

May 14, 2021
SELL
$260.64 - $382.12 $123,804 - $181,507
-475 Reduced 6.51%
6,824 $2.38 Million
Q4 2020

Feb 09, 2021
BUY
$221.31 - $316.61 $54,884 - $78,519
248 Added 3.52%
7,299 $1.89 Million
Q3 2020

Nov 13, 2020
BUY
$189.18 - $286.44 $60,537 - $91,660
320 Added 4.75%
7,051 $2.02 Million
Q2 2020

Aug 03, 2020
BUY
$123.9 - $195.41 $142,856 - $225,307
1,153 Added 20.67%
6,731 $1.27 Million
Q1 2020

May 15, 2020
SELL
$121.84 - $173.19 $386,476 - $549,358
-3,172 Reduced 36.25%
5,578 $687,000
Q4 2019

Feb 12, 2020
SELL
$115.78 - $208.34 $249,969 - $449,806
-2,159 Reduced 19.79%
8,750 $1.45 Million
Q3 2019

Nov 12, 2019
SELL
$120.61 - $148.29 $71,280 - $87,639
-591 Reduced 5.14%
10,909 $1.34 Million
Q2 2019

Aug 13, 2019
SELL
$113.99 - $146.86 $190,363 - $245,256
-1,670 Reduced 12.68%
11,500 $1.43 Million
Q1 2019

May 15, 2019
BUY
$122.82 - $151.83 $44,460 - $54,962
362 Added 2.83%
13,170 $1.74 Million
Q4 2018

Feb 14, 2019
SELL
$107.01 - $175.15 $256,931 - $420,535
-2,401 Reduced 15.79%
12,808 $1.8 Million
Q3 2018

Nov 14, 2018
SELL
$152.62 - $189.66 $56,622 - $70,363
-371 Reduced 2.38%
15,209 $2.62 Million
Q2 2018

Aug 13, 2018
BUY
$152.5 - $216.77 $394,822 - $561,217
2,589 Added 19.93%
15,580 $2.4 Million
Q1 2018

May 14, 2018
SELL
$97.41 - $177.22 $95,364 - $173,498
-979 Reduced 7.01%
12,991 $2.18 Million
Q4 2017

Feb 14, 2018
BUY
$79.6 - $114.73 $112,315 - $161,884
1,411 Added 11.23%
13,970 $1.37 Million
Q3 2017

Nov 13, 2017
BUY
$66.19 - $103.46 $161,569 - $252,545
2,441 Added 24.13%
12,559 $1.3 Million
Q2 2017

Aug 11, 2017
BUY
N/A
10,118
10,118 $455,000

Others Institutions Holding BGNE

# of Institutions
253
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email